KBTBD8/RRP15 as a potential novel therapeutic target associates with lenvatinib-inhibited progression in hepatocellular carcinoma both in vitro and in vivo
Our study elucidated a previously unidentified mechanism of lenvatinib action and identified the RRP15-KBTBD8 axis as a novel therapeutic target in HCC, offering new avenues for treatment strategies in combating HCC.
Authors
- Rui Wu (ORCID: https://orcid.org/0000-0001-7910-6614)
- Runqiu Jiang
- Saili Zhao (ORCID: https://orcid.org/0000-0001-6558-4324)
- Guifang Xu (ORCID: https://orcid.org/0000-0003-3963-8557)
- Xuran Wang
- Bin Zhang (ORCID: https://orcid.org/0000-0002-4329-2942)
- Fenglan Wang
- Zhangding Wang (ORCID: https://orcid.org/0000-0002-3959-4542)
- Wei Kang (ORCID: https://orcid.org/0000-0002-4651-677X)
- Xiaoxuan Tang
- Lei Wang
- Junhui Chen (ORCID: https://orcid.org/0000-0002-7085-0022)
- Xiaoping Zou
Institutions
- Xuzhou Medical College (CN)
- Chinese University of Hong Kong (HK)
- Anhui Medical University (CN)
- Nanjing Drum Tower Hospital (CN)
- Prince of Wales Hospital (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1016/j.jare.2024.12.017
- Citations
- 2
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Jiangsu Provincial Medical Youth Talent
- Basic Research Program of Jiangsu Province